

Table 7.8
Cancer of the Corpus and Uterus, NOS (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Diagnosis Year, Stage and Age

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	73	-	-	31	-	-
1970-1973 ^a	-	-	-	81	-	-	44	-	-
1975-1977 ^b	86.9	92.7	86.2	88.0	93.3	87.4	60.2	84.4 ^g	55.6
1978-1980 ^b	82.5	91.7	81.3	83.7	93.0	82.6	54.9	82.3 ^g	49.5
1981-1983 ^b	80.7	91.2	79.4	82.2	92.3	81.1	50.7	82.8 ^g	45.6
1984-1986 ^b	82.5	93.6	81.1	84.0	93.9	82.8	56.2	83.5 ^g	52.7
1987-1989 ^b	82.3	89.8	81.2	83.9	90.9	83.0	56.7	82.8 ^g	52.9
1990-1992 ^b	83.7	90.1	82.7	85.8	92.3	84.9	54.0	72.9 ^g	50.2
1993-1995 ^b	83.2	90.0	82.0	84.9	91.5	83.8	58.6	81.7	54.0
1996-1998 ^b	83.5	90.1	82.4	85.2	91.3	84.2	61.7	82.2	57.3
1999-2001 ^b	84.2	88.7	83.3	85.9	89.9	85.2	61.4	70.9	58.9
2002-2004 ^b	83.0	90.1	81.6	85.3	92.5	84.1	60.4	78.0	55.9
2005-2008 ^b	83.6	88.3	82.8	85.7	90.1	85.0	65.1	73.7	63.4
2009-2015 ^b	82.9 ^f	89.0 ^f	82.0 ^f	85.6 ^f	90.1 ^f	85.0 ^f	64.2 ^f	81.9	61.5 ^f
5-Year Period Survival (Percent) ^{cd}									
2015	81.0	87.8	79.9	83.3	89.0	82.5	62.1	77.4	59.8
Stage Distribution (%) 2009-2015 ^{ce}									
All Stages									
Number of cases	79,717	10,999	68,718	63,219	8,072	55,147	8,509	1,071	7,438
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	67	71	66	69	72	68	54	62	53
Regional	21	17	21	20	17	21	24	20	25
Distant	9	8	9	8	7	8	17	13	17
Unstaged/Unknown	3	4	3	3	4	3	5	6	5
5-Year Relative Survival (Percent), 2009-2015 ^c									
Age at Diagnosis:									
Ages <45	89.4	-	-	90.3	-	-	80.1	-	-
Ages 45-54	86.4	-	-	87.7	-	-	71.9	-	-
Ages 55-64	84.2	-	-	86.7	-	-	65.8	-	-
Ages 65-74	78.1	-	-	81.4	-	-	56.8	-	-
Ages 75+	67.1	-	-	70.5	-	-	41.2	-	-
Ages <65	85.5	-	-	87.4	-	-	69.2	-	-
Ages 65+	74.3	-	-	77.5	-	-	52.0	-	-
Stage ^e :									
All Stages	81.2	88.2	80.0	83.5	89.2	82.7	62.2	79.4	59.6
Localized	95.0	96.3	94.8	95.9	96.6	95.8	85.8	92.3	84.6
Regional	69.0	81.2	67.3	71.6	82.2	70.4	49.8	72.5	47.2
Distant	16.8	31.2	14.8	18.1	32.5	16.1	9.7	25.4	8.1
Unstaged/Unknown	52.9	89.0	45.6	52.0	89.3	45.5	43.6	81.5 ^g	37.7

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2016. [Expected survival rates](#) are derived from the U.S. Annual Life Tables.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

Based on follow-up of patients into 2016.

^d Period survival provides a 2015 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival), (2009-2011: 1-2 year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2009-2015 is statistically significant (p<.05).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.